Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study.

"Declarations Ethics approval and consent to participateAll patients provided written consent for inclusion into the study. ClinicalTrials.gov identifier: NCT03188172. Consent for publicationAuthors consent to publication. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding We would like to acknowledge Janssen and Celgene (for supporting the MUKnine OPTIMUM study), as well as support from Cancer Research UK National Cancer Imaging Translational Accelerator (NCITA), the National Institute for Health and Care Research (NIHR) Biomedical Research Centre and the Clinical Research Facility in Imaging at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care."

"Trial registration ClinicalTrials.gov, NCT03188172, Registered on 15 June 2017."